In addition, these antibodies can induce deleterious autoimmune effects by binding off-target, for example, diabetes mellitus after PD-L1 treatment due to PD-L1 expression by pancreatic β-cells (Fousteri, 2020). Here, CD274 is linked to diabetes mellitus.